BTK and lymphoma: This multifaceted disruption of redox homeostasis significantly enhances DLBCL cell vulnerability to ferroptosis and provides a mechanistic rationale for exploiting BTK inhibitors in combination with ferroptosis-inducing therapies in high-risk, apoptosis-refractory lymphomas.